BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee ...

Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and ...

LONDON, GREATER LONDON, UNITED KINGDOM, January 28, 2025 /EINPresswire / -- How Has the Hizentra Market Performed Historically, and What Does the Future Hold? The hizentra market size has seen ...

Financial writer covers success of Efgartigimod in myositis trials, company's strong revenue and cash position, and future ...

The prior authorization was denied. What’s more, in an unusual move, the insurer declined to allow a “peer-to-peer” review of ...

BioArctic AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector ...

This new immunoglobulin (Ig) therapeutic option will expand AIC’s ability to better serve PI patients. “We are excited to add ALGYLO™ to our expansive list of Ig infusion therapies,” said ...